Ultherapy: Ultrasound Skin Lifting Cost, Results and Pain

Ultherapy is the brand name for the Ulthera System, an ultrasound device marketed by Merz Aesthetics.

The device was first authorized by FDA through the De Novo pathway (DEN080006) in September 2009, and later treatment areas were added through 510(k) clearances.

De Novo and 510(k) are FDA's device pathways, so Ultherapy is an FDA-cleared (authorized) device, not an FDA-approved one — a page or ad that calls it "FDA-approved" is using the wrong term.

The cleared labeling describes the intended use plainly: to apply focused ultrasound energy to the body to achieve "temporary changes in the physical appearance of the skin".

In treatment, the device delivers focused ultrasound through transducers that work at fixed depths of 1.5 mm, 3.0 mm or 4.5 mm, and the system's DeepSEE imaging can visualize tissue up to 8 mm below the skin surface.

Merz markets Ultherapy as the only treatment of its kind with real-time ultrasound imaging.

The American Academy of Dermatology (AAD) places ultrasound in the middle tier of skin tightening: non-invasive procedures that can do more than creams but less than minimally invasive treatments or surgery.

In February 2024, FDA cleared an updated console, the UC-1 Control Unit PRIME (K233996).

FDA's 510(k) summary describes PRIME as a console modification with identical ultrasound signal energy and treatment guidelines to the earlier system; what changed was the industrial design, the on-screen graphics and the hardware.

Merz's site says PRIME sessions run "20% faster" than the earlier system's, a figure the site's footnote draws from a survey of providers.

A practice may have either console, and nothing in FDA's summary describes a change in energy, treatment guidelines or indications.

For more on the updated console, see what Ultherapy PRIME changes.

FDA's clearances name the areas and effects Ultherapy is meant to treat.

As of 2026, the cleared indications are to lift the eyebrow; to lift lax submental (beneath the chin) and neck tissue; to improve lines and wrinkles of the décolleté (chest); and to improve the appearance of skin laxity on the abdomen, the anterior (front) and posterior (back) arms, and the knees (K260618).

• Lifting the eyebrow was the device's original indication, authorized through the De Novo grant in 2009.
• Lifting lax under-chin and neck tissue was added in October 2012 (K121700). For the neck in detail, see Ultherapy for turkey neck.
• Improving décolleté lines and wrinkles was added in June 2014 (K134032).
• Skin laxity on the abdomen and arms was added in February 2025 (K243035), and on the knees in May 2026 (K260618).

A use that is not on this list is not a cleared use for this device, whatever a treatment menu or an advertisement suggests.

The instructions for use (IFU) are explicit that Ultherapy must not be used on the eyes, or anywhere the energy could reach the eye, and they direct the provider to avoid the thyroid gland, thyroid cartilage and trachea, and major vessels and nerves.

Merz describes a typical candidate as someone with mild to moderate skin laxity, often in their 30s or older, and is direct that Ultherapy is not a replacement for a surgical facelift.

AAD's guidance on skin tightening says the best candidates for non-invasive tightening have a small amount of sagging, a stable healthy weight, little alcohol use, no smoking and sun-protected skin, and it cautions that people with a lot of sagging skin may not benefit.

The IFU also lists people and situations the device has not been evaluated for, and conditions that rule treatment out:

• Contraindicated: open wounds or lesions in the treatment area, severe or cystic acne in the treatment area, or active implants such as pacemakers or defibrillators, or metallic implants, in the treatment area.
• Not evaluated: use over dermal fillers, mechanical implants or breast implants; patients on anticoagulants; pregnant or breastfeeding women; children; and people with conditions including bleeding disorders, herpes simplex, autoimmune disease, diabetes, epilepsy or Bell's palsy.

On skin tone, the IFU states treatment is intended for adults of all races and ethnicities, regardless of Fitzpatrick skin type.

Start with what we could not find: a reliable national price.

MedSpaStandard's research found no national price figure for Ultherapy or for ultrasound skin tightening from a major professional society or clinical source — researchers found no nonsurgical skin-tightening cost page on the American Society of Plastic Surgeons' site, and the review-site cost data they tried to check (RealSelf) was inaccessible.

A price on a clinic menu, a chain promotion or a blog post is that seller's number, not a market average we can verify.

Two cost-relevant points are on firmer ground.

Session length varies with the area treated — Merz's FAQ gives 30 to 90 minutes depending on the area — so a plan covering several areas is a longer undertaking than a single-area one.

And AAD notes that non-invasive skin tightening, ultrasound included, is not covered by insurance, so this is an out-of-pocket purchase.

Because our research turned up no national figure to check a quote against, the quote is the product.

Ask each practice for it in writing, and make it cover which area or areas are being treated, how many sessions the plan assumes, whether any touch-up is included or billed separately, and who will perform the treatment.

Where a quote looks unusually low, ask which device it covers — ultrasound devices sold under the generic label "HIFU" are a separate category whose clearance claims we could not verify, as the alternatives section below explains.

For more on pricing, see how much Ultherapy costs.

Merz says most patients see results after one Ultherapy PRIME session, with some initial lift and final results developing over 2 to 3 months.

The company says results in the face "can last up to a year or more", and its site gives the abdomen and arms a shorter window of up to 6 months.

AAD's general guidance for ultrasound tightening matches that slow onset: with one treatment, most people see modest lifting and tightening within 2 to 6 months, and more treatments may add benefit.

The evidence behind the clearances is worth reading in its own scope.

In the trial supporting the 2012 neck and under-chin clearance, 51 of 70 patients had at least 20 mm² of lift, and 84.3% of those were judged improved by masked evaluators; adverse events were mild and short-lived, with no serious adverse events.

The 2026 knee clearance took a different route: FDA relied on a literature review of 3 clinical studies with 44 total subjects showing improvement up to 180 days, plus real-world and post-market data, rather than a new dedicated trial.

Keep each figure inside its walls.

The 84.3% belongs to one trial, in one area — the submental and neck region — judged by masked evaluators; it is not a promise for any other area or any one person.

The cleared labeling frames the whole device more modestly than the marketing does: its purpose is "temporary changes in the physical appearance of the skin", which is the honest expectation to carry into a consultation.

Merz's FAQ says patients may feel heat and/or tingling during treatment, and that a session takes 30 to 90 minutes depending on the area treated.

The company says the most common side effects in clinical trials were redness, swelling, pain and transient nerve effects.

The sensation, in other words, is real, and the manufacturer's own trial summary includes pain — ask a practice before booking what they do to keep patients comfortable.

The same FAQ describes the treatment as taking place "without any downtime", with redness that typically fades within a few hours and, in some patients, slight temporary swelling, tingling or tenderness.

That is the manufacturer's description.

The cleared labeling's own timeline runs longer for some effects: redness usually resolving within hours, swelling within 3 to 72 hours, welting within a week, bruising and tenderness within 2 days to 2 weeks, and transient muscle weakness or numbness from nerve inflammation that typically resolves in 2 to 6 weeks.

So the honest picture has two layers: the manufacturer describes a treatment with no recovery period, and the cleared labeling documents effects that can last from hours to weeks.

Both come from the record; the second is the one to plan around.

In Ultherapy's face and neck trials, side effects were mild and transient — the redness, swelling, welting, bruising, tenderness and nerve-related weakness or numbness described in the timelines above — and no permanent facial nerve injuries were reported in trials.

Post-market reports are a different record: they are the reports listed in the instructions for use after the device was in wide use, and the labeling says their frequency cannot be reliably estimated from them.

That post-market list is longer and more serious than the trial list: burns or blisters, nodules, fat or volume loss, skin sagging or asymmetry, pigment change, scarring, numbness, muscle weakness (palsy or paresis), speech difficulty and vision changes.

The labeling notes that reported severity and duration have varied, and that nerve effects lasting months have been described.

Technique is part of the risk picture.

The IFU warns that burns, which may or may not cause permanent scarring, can occur with incorrect treatment technique — for example tilting the transducer, incorrect line spacing, or gel pockets under the transducer.

This is a device whose cleared labeling puts real weight on the operator, which is worth weighing when you choose a practice.

AAD sorts the tightening options into three tiers: subtle results from creams; modest tightening from non-invasive procedures — ultrasound, radiofrequency and certain lasers; and the most tightening without surgery from minimally invasive procedures, such as radiofrequency delivered under the skin through a thin tube or needles, and laser resurfacing.

AAD is blunt about the ceiling: none of them matches a facelift, eyelid surgery or neck lift, and non-surgical tightening is not a substitute for a facelift.

Within the non-invasive tier, the honest comparison today runs on cleared indications, because no head-to-head clinical trial comparing Ultherapy with Sofwave or with Thermage was located in our research pass; what exists is each device's own clearance and the manufacturer's statements.

Sofwave is the closest cleared comparator.

It is a separate FDA-cleared ultrasound system (K240687, cleared May 2024) for adults 22 and older, to improve facial lines and wrinkles, lift the eyebrow, lift lax submental and neck tissue, and give short-term improvement in the appearance of cellulite.

The two systems overlap but are not identical: Sofwave holds facial lines-and-wrinkles and short-term cellulite indications Ultherapy lacks, while Ultherapy carries décolleté, abdomen, arm and knee indications Sofwave lacks.

Any claim that Ultherapy is "the only treatment cleared by the FDA" for lifting the brow, under-chin and neck is outdated — Sofwave is cleared for those areas under its May 2024 clearance (K240687).

Radiofrequency devices carry different wording.

Thermage FLX is cleared for non-invasive treatment of wrinkles and rhytids, including periorbital wrinkles on the upper and lower eyelids — an area the Ulthera IFU forbids — but its cleared text does not say "skin tightening" or "lifting".

InMode's Morpheus8 RF microneedling applicators are cleared for dermatologic procedures requiring coagulation or contraction of soft tissue, or hemostasis; that clearance does not list skin tightening, wrinkles or acne scars.

Ultrasound devices sold under the generic label "HIFU" are a separate category.

MedSpaStandard could not verify clearance claims for unbranded HIFU devices in this research pass; Ultherapy and Sofwave have specific 510(k) clearances with defined indications, and any other device's clearance can be checked individually in FDA's public 510(k) database.

Choosing among them is a conversation to have with a licensed provider, but the questions travel well: which cleared indications cover the area you want treated, what evidence exists for results there, and which device the practice actually owns and operates.

Start with the device and its paperwork.

Ask which areas the practice treats with Ultherapy and check them against the cleared list in this guide; a use that is not on the list is not a cleared use, and that is worth knowing before you pay, not after.

Then ask who performs it.

AmSpa, a med spa trade association, says injecting a prescription drug such as botulinum toxin is the practice of medicine, so it must be done by a licensed professional acting within their scope, under rules that vary by state.

Ultherapy is a device rather than an injectable; ask the practice directly who will run the treatment, what that person's license is, and what training they have on this specific device.

A practice should screen every patient against the IFU before treatment: open wounds, severe or cystic acne, implants in the area, anticoagulant therapy, pregnancy and the labeling's other exclusions.

If nobody asks about your medical history, your fillers or your medications, read that as information about the practice.

Money and photos, in that order.

Get the quote in writing, with the areas and sessions it covers, since our research found no national price to check it against.

And weigh before-and-after photos with the FTC's rule in mind: the agency's endorsement guides say a before-and-after picture paired with a results claim is likely to convey that the result is typical, and that an advertiser who cannot substantiate that should clearly and conspicuously disclose the results consumers can generally expect.

Ask what the generally expected result looks like — not just which photo the practice likes best.